Pparδ agonist 5

Cat. No.:	HY-141494
Molecular Formula:	$C_{23}H_{21}F_3N_2O_2S$
Molecular Weight:	446.49
Target:	PPAR
Pathway:	Cell Cycle/DNA Damage; Vitamin D Related/Nuclear Receptor
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Pparδ agonist 5, an orally active PPARδ-selective agonist (EC_{50}=0.335 μM), is much greater than that of the prototypical standard GW0742. Pparδ agonist 5 promotes improvements in bone density and microarchitecture in vivo[1].
IC_{50} & Target	PPARδ 0.335 μM (EC50)
In Vivo	Pparδ agonist 5 (compound 31a) shows an even greater improvement in the trabecular structure, comparable to or slightly better than GW0742[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 female mice[1]
Dosage:	10 mg per kg of body weight
Administration:	P.o.; per day for 6 weeks
Result:	Improved the bone density at least back to normal (sham control) levels.

REFERENCES

[1]. Kress BJ, et al. Synthesis and Evaluation of PPARδ Agonists That Promote Osteogenesis in a Human Mesenchymal Stem Cell Culture and in a Mouse Model of Human Osteoporosis. J Med Chem. 2021;64(10):6996-7032.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA